FDA Determines Regulatory Review Period for VIMPAT Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VIMPAT, a human drug product, based on a new drug application (NDA) 22-253, and is publishing this notice as required by law. This decision was made in response to patent extension applications submitted to the Director of Patents and Trademarks at the Department of Commerce.